Eduarda Talita Bramorski Mohr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eduarda Talita Bramorski Mohr has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Monguilhott Dalmarco
Department of Clinical Analysis, Center of Health Sciences, Federal University of Santa Catarina (UFSC), Campus Universitario‑Trindade, Florianopolis, Brazil
9 shared publications - Ianka Cristina Celuppi
Universidade Federal de Santa Catarina, Brazil
5 shared publications - Jades Fernando Hammes
Bridge Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil
5 shared publications - Júlia Meller Dias de Oliveira
Laboratório Bridge, Brasil; UFSC, Brasil
5 shared publications - Raul Sidnei Wazlawick
Laboratório Bridge, Brasil; UFSC, Brasil
5 shared publications - Mariano Felisberto
Bridge Laboratory, Federal University of Santa Catarina, Florianópolis, Brazil; Department of Clinical Analysis, Federal University of Santa Catarina, Florianópolis, Brazil
3 shared publications
Latest Publications
- 25 August 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 197 (Pt A) , 110983
Mapping the evaluation of Brazil's national electronic health system for primary care (PEC e-SUS APS): a scoping review
- 25 August 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 197 (Pt A) , 110983
Mapping the evaluation of Brazil's national electronic health system for primary care (PEC e-SUS APS): a scoping review
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 30 (6) , e02972025
Aplicativo e-SUS Vacinação: uma tecnologia da estratégia e-SUS APS para campanhas de vacinação do Sistema Único de Saúde
Resumo Durante a pandemia de COVID-19, o uso de tecnologias digitais facilitou a comunicação entre profissionais, pacientes e sistemas de saúde. A incorporação dessas tecnologias fortaleceu a resiliência dos sistemas públicos de saúde, colaborando para o enfrentamento direto da pandemia. O objetivo deste trabalho é descrever o desenvolvimento, utilização e adequação do e-SUS Vacinação durante e após a pandemia de COVID-19 no Brasil, destacando suas contribuições para a resiliência do Sistema Único de Saúde. Este estudo incluiu um desenho descritivo que analisa o desenvolvimento e a aplicação do e-SUS Vacinação, avaliando o aplicativo por meio de comparação de dados preenchidos, projetos pilotos, análises do Google Analytics e questionários de usabilidade dos usuários. O aplicativo demonstrou uma redução de até 95% no tempo de preenchimento das informações, com mais de 338 mil imunobiológicos aplicados por 107 mil usuários ativos. A usabilidade do aplicativo foi avaliada em 4,10, demonstrando um parecer favorável proveniente dos usuários. Sendo assim, o e-SUS Vacinação evidenciou a resiliência de tecnologias digitais na saúde, reforçando sua importância para a continuidade e eficácia das campanhas de imunização no Brasil.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 30 (6) , e02972025
Open AccessAplicativo e-SUS Vacinação: uma tecnologia da estratégia e-SUS APS para campanhas de vacinação do Sistema Único de Saúde
Resumo Durante a pandemia de COVID-19, o uso de tecnologias digitais facilitou a comunicação entre profissionais, pacientes e sistemas de saúde. A incorporação dessas tecnologias fortaleceu a resiliência dos sistemas públicos de saúde, colaborando para o enfrentamento direto da pandemia. O objetivo deste trabalho é descrever o desenvolvimento, utilização e adequação do e-SUS Vacinação durante e após a pandemia de COVID-19 no Brasil, destacando suas contribuições para a resiliência do Sistema Único de Saúde. Este estudo incluiu um desenho descritivo que analisa o desenvolvimento e a aplicação do e-SUS Vacinação, avaliando o aplicativo por meio de comparação de dados preenchidos, projetos pilotos, análises do Google Analytics e questionários de usabilidade dos usuários. O aplicativo demonstrou uma redução de até 95% no tempo de preenchimento das informações, com mais de 338 mil imunobiológicos aplicados por 107 mil usuários ativos. A usabilidade do aplicativo foi avaliada em 4,10, demonstrando um parecer favorável proveniente dos usuários. Sendo assim, o e-SUS Vacinação evidenciou a resiliência de tecnologias digitais na saúde, reforçando sua importância para a continuidade e eficácia das campanhas de imunização no Brasil.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 30 (6) , e02972025
e-SUS Vacinação application: an e-SUS APS strategy technology for vaccination campaigns in the Unified Health System
During the COVID-19 pandemic, digital technologies facilitated communication between professionals, patients, and health systems. Incorporating these technologies enhanced the resilience of public health systems, contributing to the direct response to the pandemic. This paper aims to describe the development, use, and adaptation of the e-SUS Vacinação application during and after the COVID-19 pandemic in Brazil, highlighting its contributions to the resilience of the Unified Health System (SUS). This study included a descriptive design that analyzes the development and application of e-SUS Vacinação, evaluating the application through data comparison, pilot projects, Google Analytics analyses, and client usability surveys. The application showed a reduction of up to 95% in the time required to complete the information, with over 338,000 immunobiologicals administered by 107,000 active users. The application’s usability was rated at 4.10, indicating a favorable response from users. Therefore, e-SUS Vacinação exemplifies the resilience of digital technologies in healthcare, reinforcing their importance for the continuity and effectiveness of Brazilian vaccination campaigns.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 30 (6) , e02972025
Open Accesse-SUS Vacinação application: an e-SUS APS strategy technology for vaccination campaigns in the Unified Health System
During the COVID-19 pandemic, digital technologies facilitated communication between professionals, patients, and health systems. Incorporating these technologies enhanced the resilience of public health systems, contributing to the direct response to the pandemic. This paper aims to describe the development, use, and adaptation of the e-SUS Vacinação application during and after the COVID-19 pandemic in Brazil, highlighting its contributions to the resilience of the Unified Health System (SUS). This study included a descriptive design that analyzes the development and application of e-SUS Vacinação, evaluating the application through data comparison, pilot projects, Google Analytics analyses, and client usability surveys. The application showed a reduction of up to 95% in the time required to complete the information, with over 338,000 immunobiologicals administered by 107,000 active users. The application’s usability was rated at 4.10, indicating a favorable response from users. Therefore, e-SUS Vacinação exemplifies the resilience of digital technologies in healthcare, reinforcing their importance for the continuity and effectiveness of Brazilian vaccination campaigns.
- 20 September 2024
- Published by Springer Nature in Health and Technology
- Vol. 14 (6) , 1083-1096
Digital signatures in electronic health records: a scoping review
- 20 September 2024
- Published by Springer Nature in Health and Technology
- Vol. 14 (6) , 1083-1096
Digital signatures in electronic health records: a scoping review
- 21 August 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (10) , 2895-2911
Thiazolidines derivatives and their anti-inflammatory activity in LPS-induced RAW 264.7 macrophages: a systematic review and meta-analysis
Thiazolidine scaffolds have been investigated for decades, due to their wide range of biological activity. In this way, the main objective of this systematic review was to elucidate the anti-inflammatory activity of thiazolidine derivatives against nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. From 9718 identified registers, 13 articles were included, where 11 studies evaluated thiazolidinediones. The summary of relevance demonstrated that seven studies (53.8%) were relevant without restrictions, and 6 (46.2%) were relevant with restrictions. The certainty in cumulative evidence was considered moderate and the six studies included in the meta-analysis demonstrated the positive activity of thiazolidinediones against NO production when compared to the negative LPS control.
- 21 August 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 39 (10) , 2895-2911
Thiazolidines derivatives and their anti-inflammatory activity in LPS-induced RAW 264.7 macrophages: a systematic review and meta-analysis
Thiazolidine scaffolds have been investigated for decades, due to their wide range of biological activity. In this way, the main objective of this systematic review was to elucidate the anti-inflammatory activity of thiazolidine derivatives against nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. From 9718 identified registers, 13 articles were included, where 11 studies evaluated thiazolidinediones. The summary of relevance demonstrated that seven studies (53.8%) were relevant without restrictions, and 6 (46.2%) were relevant with restrictions. The certainty in cumulative evidence was considered moderate and the six studies included in the meta-analysis demonstrated the positive activity of thiazolidinediones against NO production when compared to the negative LPS control.
- Open Access
- 21 February 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Saúde Pública
- Vol. 58 (1) , 23
Dez anos do Prontuário Eletrônico do Cidadão e-SUS APS: em busca de um Sistema Único de Saúde eletrônico
OBJETIVO: Contextualizar a adesão ao Prontuário Eletrônico do Cidadão (PEC) pelos municípios brasileiros e a evolução da estratégia eletrônica do Sistema Único de Saúde (e-SUS) da Atenção Primária (APS) durante seus 10 anos. MÉTODOS: Trata-se de um estudo de cunho descritivo, que agregou informações de adesão ao uso do prontuário, extraídas da base de dados da Secretaria de Atenção Primária à Saúde (SAPS) do Governo Federal, entre os anos de 2017 e 2022. Foram analisados o quantitativo de unidades básicas de saúde informatizadas que utilizavam algum prontuário eletrônico e o número das que utilizavam a Coleta de Dados Simplificada (CDS) e das que implementaram o Prontuário Eletrônico do Cidadão (PEC), no mesmo período. Também foi realizada uma síntese descritiva das funcionalidades e módulos que foram implementados no sistema durante seus 10 anos de desenvolvimento. RESULTADOS: A adesão dos municípios brasileiros ao PEC cresceu exponencialmente nos últimos cinco anos, passando de 8.930 unidades de saúde em 2017 para 26.091 em 2022. Como era de se esperar, as principais funcionalidades e melhorias desenvolvidas nessa década buscaram implementar novos fluxos e módulos de processos administrativos, de atendimento clínico e de gestão do cuidado e administração do serviço de saúde, mas também foram importantes para o sucesso do sistema aprimorar aspectos de usabilidade e de infraestrutura tecnológica da arquitetura da aplicação. CONCLUSÕES: Em 2023, celebra-se o marco de uma década do início da implantação do prontuário pelos municípios brasileiros, marcado por desafios de ordem tecnológica e de infraestrutura, bem como de melhorias e novas funcionalidades que evidenciaram a evolução tecnológica do sistema e da estratégia e-SUS APS. Mesmo que muitas outras existam, pode-se dizer que o PEC é hoje a principal ferramenta de prontuário eletrônico no Brasil, pois sempre investiu em evolução, vindo a se atualizar nas oportunidades tecnológicas e de usabilidade.
- 21 February 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Saúde Pública
- Vol. 58 (1) , 23
Open AccessDez anos do Prontuário Eletrônico do Cidadão e-SUS APS: em busca de um Sistema Único de Saúde eletrônico
OBJETIVO: Contextualizar a adesão ao Prontuário Eletrônico do Cidadão (PEC) pelos municípios brasileiros e a evolução da estratégia eletrônica do Sistema Único de Saúde (e-SUS) da Atenção Primária (APS) durante seus 10 anos. MÉTODOS: Trata-se de um estudo de cunho descritivo, que agregou informações de adesão ao uso do prontuário, extraídas da base de dados da Secretaria de Atenção Primária à Saúde (SAPS) do Governo Federal, entre os anos de 2017 e 2022. Foram analisados o quantitativo de unidades básicas de saúde informatizadas que utilizavam algum prontuário eletrônico e o número das que utilizavam a Coleta de Dados Simplificada (CDS) e das que implementaram o Prontuário Eletrônico do Cidadão (PEC), no mesmo período. Também foi realizada uma síntese descritiva das funcionalidades e módulos que foram implementados no sistema durante seus 10 anos de desenvolvimento. RESULTADOS: A adesão dos municípios brasileiros ao PEC cresceu exponencialmente nos últimos cinco anos, passando de 8.930 unidades de saúde em 2017 para 26.091 em 2022. Como era de se esperar, as principais funcionalidades e melhorias desenvolvidas nessa década buscaram implementar novos fluxos e módulos de processos administrativos, de atendimento clínico e de gestão do cuidado e administração do serviço de saúde, mas também foram importantes para o sucesso do sistema aprimorar aspectos de usabilidade e de infraestrutura tecnológica da arquitetura da aplicação. CONCLUSÕES: Em 2023, celebra-se o marco de uma década do início da implantação do prontuário pelos municípios brasileiros, marcado por desafios de ordem tecnológica e de infraestrutura, bem como de melhorias e novas funcionalidades que evidenciaram a evolução tecnológica do sistema e da estratégia e-SUS APS. Mesmo que muitas outras existam, pode-se dizer que o PEC é hoje a principal ferramenta de prontuário eletrônico no Brasil, pois sempre investiu em evolução, vindo a se atualizar nas oportunidades tecnológicas e de usabilidade.
- Open Access
- 17 February 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024, 1-12
Interference in Macrophage Balance (M1/M2): The Mechanism of Action Responsible for the Anti-Inflammatory Effect of a Fluorophenyl-Substituted Imidazole
Traditionally, the treatment of inflammatory conditions has focused on the inhibition of inflammatory mediator production; however, many conditions are refractory to this classical approach. Recently, an alternative has been presented by researchers to solve this problem: The immunomodulation of cells closely related to inflammation. Hence, macrophages, a critical key in both innate and acquired immunity, have been presented as an alternative target for the development of new medicines. In this work, we tested the fluorophenyl-imidazole for its anti-inflammatory activity and possible immunomodulatory effect on RAW 264.7 macrophages. We also evaluated the anti-inflammatory effect of the compound, and the macrophage repolarization to M2 was confirmed by the ability of the compound to reduce the M1 markers TNF-α, IL-6, MCP-1, IL-12p70, IFN-γ, and TLR4, the high levels of p65 phosphorylated, iNOS and COX-2 mRNA expression, and the fact that the compound was not able to induce the production of M1 markers when used in macrophages without lipopolysaccharide (LPS) stimulation. Moreover, fluorophenyl-imidazole had the ability to increase the M2 markers IL-4, IL-13, CD206, apoptosis and phagocytosis levels, arginase-1, and FIZZ-1 mRNA expression before LPS stimulation. Similarly, it was also able to induce the production of these same M2 markers in macrophages without being induced with LPS. These results reinforce the affirmation that the fluorophenyl-imidazole has an important anti-inflammatory effect and demonstrates that this effect is due to immunomodulatory activity, having the ability to trigger a repolarization of macrophages from M1 to M2a. These facts suggest that this molecule could be used as an alternative scaffold for the development of a new medicine to treat inflammatory conditions, where the anti-inflammatory and proregenerative properties of M2a macrophages are desired.
- 17 February 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024, 1-12
Open AccessInterference in Macrophage Balance (M1/M2): The Mechanism of Action Responsible for the Anti-Inflammatory Effect of a Fluorophenyl-Substituted Imidazole
Traditionally, the treatment of inflammatory conditions has focused on the inhibition of inflammatory mediator production; however, many conditions are refractory to this classical approach. Recently, an alternative has been presented by researchers to solve this problem: The immunomodulation of cells closely related to inflammation. Hence, macrophages, a critical key in both innate and acquired immunity, have been presented as an alternative target for the development of new medicines. In this work, we tested the fluorophenyl-imidazole for its anti-inflammatory activity and possible immunomodulatory effect on RAW 264.7 macrophages. We also evaluated the anti-inflammatory effect of the compound, and the macrophage repolarization to M2 was confirmed by the ability of the compound to reduce the M1 markers TNF-α, IL-6, MCP-1, IL-12p70, IFN-γ, and TLR4, the high levels of p65 phosphorylated, iNOS and COX-2 mRNA expression, and the fact that the compound was not able to induce the production of M1 markers when used in macrophages without lipopolysaccharide (LPS) stimulation. Moreover, fluorophenyl-imidazole had the ability to increase the M2 markers IL-4, IL-13, CD206, apoptosis and phagocytosis levels, arginase-1, and FIZZ-1 mRNA expression before LPS stimulation. Similarly, it was also able to induce the production of these same M2 markers in macrophages without being induced with LPS. These results reinforce the affirmation that the fluorophenyl-imidazole has an important anti-inflammatory effect and demonstrates that this effect is due to immunomodulatory activity, having the ability to trigger a repolarization of macrophages from M1 to M2a. These facts suggest that this molecule could be used as an alternative scaffold for the development of a new medicine to treat inflammatory conditions, where the anti-inflammatory and proregenerative properties of M2a macrophages are desired.
- Open Access
- 31 January 2024
- Published by Wiley
Anti-inflammatory screening biomarkers on an LPS-induced RAW 264.7 cell model: a Systematic Review and Meta-analysis.
The inflammation is a response to some injury aimed at reestablishing homeostasis of the affected tissue. The in vitro model using RAW 264.7 cells has been widely used, as experimental model to assess the inflammatory response. However, there is still no consensus on which inflammatory mediators should initially be measured to screen for possible anti-inflammatory effects. To determine the rationality of measuring different inflammatory mediators together with NO, we carried out this systematic review and meta-analysis. A total of 17 studies were included, and LPS-induced cells produced high NO levels compared to non-LPS induced, and this production was not related to cell density. TNF-α, IL-1β, and IL-6, also showed high levels after cells had been stimulated with LPS; however, these effects were related to cell density. Finally, was found that measurement of NO levels alone may be sufficient to screen for possible anti-inflammatory action in the context of this model.
- 31 January 2024
- Published by Wiley
Open AccessAnti-inflammatory screening biomarkers on an LPS-induced RAW 264.7 cell model: a Systematic Review and Meta-analysis.
The inflammation is a response to some injury aimed at reestablishing homeostasis of the affected tissue. The in vitro model using RAW 264.7 cells has been widely used, as experimental model to assess the inflammatory response. However, there is still no consensus on which inflammatory mediators should initially be measured to screen for possible anti-inflammatory effects. To determine the rationality of measuring different inflammatory mediators together with NO, we carried out this systematic review and meta-analysis. A total of 17 studies were included, and LPS-induced cells produced high NO levels compared to non-LPS induced, and this production was not related to cell density. TNF-α, IL-1β, and IL-6, also showed high levels after cells had been stimulated with LPS; however, these effects were related to cell density. Finally, was found that measurement of NO levels alone may be sufficient to screen for possible anti-inflammatory action in the context of this model.
- Open Access
- 3 November 2019
- Published by Wiley in Mediators of Inflammation
- Vol. 2019, 1-12
Evidence That the Anti-Inflammatory Effect of Rubiadin-1-methyl Ether Has an Immunomodulatory Context
Background. In spite of the latest therapeutic developments, no effective treatments for handling critical conditions such as acute lung injuries have yet been found. Such conditions, which may result from lung infections, sepsis, multiple trauma, or shock, represent a significant challenge in intensive care medicine. Seeking ways to better deal with this challenge, the scientific community has recently devoted much attention to small molecules derived from natural products with anti-inflammatory and immunomodulatory effects.Aims. In this context, we investigated the anti-inflammatory effect of Rubiadin-1-methyl ether isolated fromPentas schimperi, using anin vitromodel of RAW 264.7 macrophages induced by LPS and anin vivomodel of acute lung injury (ALI) induced by LPS.Methods. The macrophages were pretreated with the compound and induced by LPS (1 μg/mL). After 24 h, using the supernatant, we evaluated the cytotoxicity, NOx, and IL-6, IL-1β, and TNF-αlevels, as well as the effect of the compound on macrophage apoptosis. Next, the compound was administered in mice with acute lung injury (ALI) induced by LPS (5 mg/kg), and the pro- and anti-inflammatory parameters were analyzed after 12 h using the bronchoalveolar lavage fluid (BALF).Results. Rubiadin-1-methyl ether was able to inhibit the pro-inflammatory parameters studied in thein vitroassays (NOx, IL-6, and IL-1β) and, at the same time, increased the macrophage apoptosis rate. In thein vivoexperiments, this compound was capable of decreasing leukocyte infiltration; fluid leakage; NOx; IL-6, IL-12p70, IFN-γ, TNF-α, and MCP-1 levels; and MPO activity. In addition, Rubiadin-1-methyl ether increased the IL-10 levels in the bronchoalveolar lavage fluid (BALF).Conclusions. These findings support the evidence that Rubiadin-1-methyl ether has important anti-inflammatory activity, with evidence of an immunomodulatory effect.
- 3 November 2019
- Published by Wiley in Mediators of Inflammation
- Vol. 2019, 1-12
Open AccessEvidence That the Anti-Inflammatory Effect of Rubiadin-1-methyl Ether Has an Immunomodulatory Context
Background. In spite of the latest therapeutic developments, no effective treatments for handling critical conditions such as acute lung injuries have yet been found. Such conditions, which may result from lung infections, sepsis, multiple trauma, or shock, represent a significant challenge in intensive care medicine. Seeking ways to better deal with this challenge, the scientific community has recently devoted much attention to small molecules derived from natural products with anti-inflammatory and immunomodulatory effects.Aims. In this context, we investigated the anti-inflammatory effect of Rubiadin-1-methyl ether isolated fromPentas schimperi, using anin vitromodel of RAW 264.7 macrophages induced by LPS and anin vivomodel of acute lung injury (ALI) induced by LPS.Methods. The macrophages were pretreated with the compound and induced by LPS (1 μg/mL). After 24 h, using the supernatant, we evaluated the cytotoxicity, NOx, and IL-6, IL-1β, and TNF-αlevels, as well as the effect of the compound on macrophage apoptosis. Next, the compound was administered in mice with acute lung injury (ALI) induced by LPS (5 mg/kg), and the pro- and anti-inflammatory parameters were analyzed after 12 h using the bronchoalveolar lavage fluid (BALF).Results. Rubiadin-1-methyl ether was able to inhibit the pro-inflammatory parameters studied in thein vitroassays (NOx, IL-6, and IL-1β) and, at the same time, increased the macrophage apoptosis rate. In thein vivoexperiments, this compound was capable of decreasing leukocyte infiltration; fluid leakage; NOx; IL-6, IL-12p70, IFN-γ, TNF-α, and MCP-1 levels; and MPO activity. In addition, Rubiadin-1-methyl ether increased the IL-10 levels in the bronchoalveolar lavage fluid (BALF).Conclusions. These findings support the evidence that Rubiadin-1-methyl ether has important anti-inflammatory activity, with evidence of an immunomodulatory effect.